Squamous Cell Carcinoma Of Head And Neck

A randomized phase 3 trial designed to evaluate xevinapant with chemoradiotherapy as treatment for certain patients with head and neck cancers has been discontinued due to likely lack of benefit, according to the agent’s manufacturer.